StockData
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. (VVOS) company profile

VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.08−0.00 (-3.04%)

Close on Nov 17, 2026Market cap $1.60MP/E –Yield –

About Vivos Therapeutics

Surgical & Medical Instruments & Apparatus, SIC 3841

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing non-surgical treatments for patients suffering from obstructive sleep apnea (OSA), snoring, and related dentofacial abnormalities. Its primary offering is The Vivos Method, a multi-disciplinary treatment protocol utilizing proprietary oral appliances alongside clinical guidance. The company also provides home sleep testing services—such as the SleepImage ring—myofunctional therapy, and medical billing intelligence services. Through its management organizations, the business supports affiliated sleep testing centers and treatment facilities. Vivos Therapeutics serves adult and pediatric patients diagnosed with sleep breathing disorders, offering its products and clinical support through dentists, medical sleep specialists, physicians, and affiliated clinical practices.

The company is headquartered in Littleton, Colorado, where it maintains principal executive offices. Its clinical and administrative presence includes operations in Nevada following its acquisition of The Sleep Center of Nevada, with additional affiliations across the United States.

Summary of the business section of Vivos Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Vivos Therapeutics, Inc.
Headquarters
Littleton, CO
Address
7921 Southpark Plaza,, Suite 210 80120
Phone
(866) 908-4867
Website
vivos.com
Employees
268, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, Denver, Colorado

Stock & identifiers

Ticker
VVOS
Exchange
Nasdaq
IPO date
Dec 14, 2020
Shares outstanding
20M, Aug 13, 2026
Public float
$22.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Oct 27, 2023
SEC CIK
1716166
CUSIP
92859E207
ISIN
US92859E2072
FIGI
BBG00H1NZV76
Share class FIGI
BBG00H1NZV85
EIN
81-3224056

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ronald Kirk HuntsmanChief Executive Officer, Director158,971
Bradford K. AmmanPrincipal Accounting Officer250,080
Anja B. KrammerDirector–
Mark F. LindsayDirector–
Ralph Elias GreenDirector–
Gregg C. JohnsonDirector3,997
Leonard J. SokolowDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$511.08K-$239.04K$357.58K$16–
FY2024$1.31M$1.85M$705.92K$34–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
R. Kirk Huntsman
Chief Executive Officer
$408.70K$801.58K$77.70K$18.93K$1.31M+130%
Bradford Amman
Chief Financial Officer
$267.64K$390.82K$26.37K$21.95K$705.92K+108%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 14, 2020
Offer price
$6.00
Securities offered
3,500,000
Gross proceeds
$21.00M
Exchange
Nasdaq
First trading day
Dec 11, 2020
First-day close
$8.99+49.8%
Lock-up ends (est.)
Jun 9, 2021

“The initial public offering price is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of December 31, 2025, we had 268 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 19, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 1, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 8, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2026Late filingNotification of late filing
Apr 22, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2026Late filingNotification of late filing
Nov 14, 2025Late filingNotification of late filing
Aug 25, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 14, 2025Late filingNotification of late filing
Jun 6, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
May 17, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 21, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 21, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 15, 2023Late filingNotification of late filing
May 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2023Late filingNotification of late filing
May 9, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 27, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 29, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 4, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 15, 2022Late filingNotification of late filing
Dec 14, 2020IPOInitial public offering priced (424B4 prospectus)
Dec 10, 2020ListingRegistration of securities on an exchange (Form 8-A)
Sep 29, 2017Name changeName changed from Vivos BioTechnologies, Inc. to Vivos Therapeutics, Inc.

See a number that looks wrong?